<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360164</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-HA-1.0(2010)</org_study_id>
    <nct_id>NCT01360164</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia</brief_title>
  <official_title>Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Brain Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing University Medical College Affiliated Wuxi Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive
      incoordination of gait and often associated with poor coordination of hands, speech, and eye
      movements. Current treatments for Hereditary Ataxias are mainly pharmacological,
      rehabilitative, or psychological treatments，while no effective treatment available. Stem Cell
      therapy is a novel and promising therapeutic strategy for Hereditary Ataxias treatment. In
      this study, the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells
      transplantation will be evaluated in patients with Hereditary Ataxias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study is designed to evaluate the the safety and efficacy of Human Umbilical Cord
      Mesenchymal Stem Cells transplantation in patients with Hereditary Ataxias.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>scores of International Cooperative Ataxia Rating Scale （ICARS） scale and Berg Scale</measure>
    <time_frame>1 year after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the volume of Cerebellum of Brain Magnetic Resonance Imaging （MRI） Scan</measure>
    <time_frame>1 year after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hereditary Ataxia</condition>
  <arm_group>
    <arm_group_label>Human umbilical cord mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Participants will be given hUC-MSCs transplantation.</description>
    <arm_group_label>Human umbilical cord mesenchymal stem cells transplantation</arm_group_label>
    <other_name>Intervention Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 16-65 years.

          -  Harding Diagnosis of SCAs, gene type confirmed.

          -  Candidates who did not receive any stem cell therapy in past 6months.

          -  sign the consent form and follow the clinic trail procedure.

        Exclusion Criteria:

          -  Cardiac insufficiency; Renal insufficiency; hepatic insufficiency; Total bilirubin
             higher than 1.5 times of upper limit of normal value; AST /ALT higher than 2.5 times
             of upper limit of normal value；

          -  Routine Blood Test: WBC count &lt;3.0×109/ L; PLT count &lt;5×109/L ; or Hemoglobin &lt;100g/L；

          -  Combined Pneumonia or other Severe systemic bacteria infection；

          -  Severe drug allergic history or anaphylaxis to 2 or more food or medicine；

          -  Other brain organic disease (eg. Brain cancer)；

          -  HIV+, Tumor Markers + ；

          -  Severe psychotic patients, cognitive dysfunction， or can not understand or sign the
             Consent Form；

          -  Other severe systemic or organic disease；

          -  Uncontrolled hypertension，blood pressure≥180mmHg/110 mmHg after treatment；

          -  Pregnancy；

          -  Enrollment in other trials in the last 3 months；

          -  Other criteria the investigator consider improper for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yun Xu</last_name>
    <email>xuyun20042001@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing University Medical College Affiliated Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Xu</last_name>
      <email>xuyun20042001@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

